致淀粉样变的轻链是一种应激原,使浆细胞对蛋白酶体抑制剂毒性敏感
研究纯化并比较了AL淀粉样变患者来源的浆细胞与多发性骨髓瘤原代浆细胞,发现AL浆细胞对蛋白酶体抑制剂具有前所未有的内在敏感性,且高于MM浆细胞,伴随独特细胞器特征和应激相关转录本表达。工程化浆细胞系实验表明AL轻链表达改变细胞生长和蛋白质稳态并赋予PI敏感性,提示致淀粉样变轻链产生是浆细胞内在应激原。
要点
- AL淀粉样变患者浆细胞对蛋白酶体抑制剂的内在敏感性高于多发性骨髓瘤浆细胞。
- AL浆细胞显示扩张的内质网、核周线粒体和应激相关转录本丰度升高。
- AL轻链表达改变浆细胞生长和蛋白质稳态并赋予蛋白酶体抑制剂敏感性。
核心结论
- 致淀粉样变轻链产生是浆细胞的内在应激原,应激反应通路是新的潜在治疗靶点。
- 研究提供了可用于解析AL浆细胞生物学的细胞疾病模型。
研究设计与样本
- 纯化并研究患者来源的AL淀粉样变浆细胞,与原发性多发性骨髓瘤浆细胞进行比较。
- 对浆细胞进行功能、生化和形态学表征。
- 构建可诱导表达致淀粉样变和非致淀粉样变轻链的浆细胞系进行机制验证。
主要发现
- AL浆细胞对蛋白酶体抑制剂的内在敏感性高于MM浆细胞。
- AL浆细胞呈现扩张的内质网、核周线粒体和应激相关转录本丰度升高,与自噬对细胞器稳态控制减弱一致。
- AL轻链表达改变细胞生长和蛋白质稳态并赋予蛋白酶体抑制剂敏感性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic light chain (AL) amyloidosis is caused by the clonal production of an unstable immunoglobulin light chain (LC), which affects organ function systemically. Although pathogenic LCs have been characterized biochemically, little is known about the biology of amyloidogenic plasma cells (PCs). Intrigued by the unique response rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we purified and investigated patient-derived AL PCs, in comparison with primary multiple myeloma (MM) PCs, the prototypical PI-responsive cells. Functional, biochemical, and morphological characterization revealed an unprecedented intrinsic sensitivity of AL PCs to PIs, even higher than that of MM PCs, associated with distinctive organellar features and expression patterns indicative of cellular stress. These consisted of expanded endoplasmic reticulum (ER), perinuclear mitochondria, and a higher abundance of stress-related transcripts, and were consistent with reduced autophagic control of organelle homeostasis. To test whether PI sensitivity stems from AL LC production, we engineered PC lines that can be induced to express amyloidogenic and nonamyloidogenic LCs, and found that AL LC expression alters cell growth and proteostasis and confers PI sensitivity. Our study discloses amyloidogenic LC production as an intrinsic PC stressor, and identifies stress-responsive pathways as novel potential therapeutic targets. Moreover, we contribute a cellular disease model to dissect the biology of AL PCs.
引用
- Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017. PMID: 28130214. doi:10.1182/blood-2016-08-730978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。